Neuland Laboratories
Neuland Laboratories Limited, commonly referred to as Neuland Labs, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to both domestic and international markets. With a strong focus on quality and innovation, Neuland Labs offers a diverse range of products, including custom synthesis and contract manufacturing services. The company is renowned for its expertise in complex molecules and has achieved significant milestones, such as obtaining multiple regulatory approvals from global health authorities. Neuland Labs is well-positioned in the market, recognised for its commitment to sustainability and customer-centric solutions. Its strategic operational regions extend across North America, Europe, and Asia, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Neuland Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuland Laboratories's score of 61 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neuland Laboratories's reported carbon emissions
In 2024, Neuland Laboratories, headquartered in India, reported total greenhouse gas emissions of approximately 57,000,000 kg CO2e. This includes Scope 1 emissions of about 22,961,440 kg CO2e, Scope 2 emissions of around 31,406,360 kg CO2e, and Scope 3 emissions of approximately 3,036,820 kg CO2e. The previous year, 2023, saw total emissions of about 69,000,000 kg CO2e, with Scope 1 at 27,442,350 kg CO2e, Scope 2 at 27,245,080 kg CO2e, and Scope 3 at 5,406,000 kg CO2e. Neuland Laboratories has committed to significant climate action through the Science Based Targets initiative (SBTi). They aim to reduce Scope 1 emissions by 30% from 2020 levels by 2030 and to achieve near-zero Scope 1 and Scope 2 emissions by 2025. Additionally, they plan to reduce Scope 2 emissions by 25% from 2020 levels by 2030. Long-term goals include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, alongside a 90% reduction in Scope 3 emissions. The company has also implemented initiatives to lower coal consumption at manufacturing facilities, directly impacting Scope 1 emissions. Their overall strategy aligns with industry standards for climate commitments, reflecting a robust approach to sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 21,134,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 19,598,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neuland Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
